Renata Montes Garcia Barbosa

Ms. Renata Montes Garcia Barbosa


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
RBRenata Montes Garcia Barbosa
Renata Montes Garcia Barbosa
MSMiriam Soares
Miriam Soares
DPDenise Maria Meneses Cury Portela
Denise Maria Meneses Cury Portela
TGThiago Gonçalves Guimarães
Thiago Gonçalves Guimarães
RCRubens Gisbert Cury
Rubens Gisbert Cury
Deep Brain Stimulation (DBS) is an effective treatment option for patients with dopaminergic complications of Parkinson’s disease (PD) and drug-refractory PD tremor. However, DBS and its indications can be challenging, and they are not often debated in the medical community. Through a critical narrative review, the objective of this paper is to improve the comprehension of DBS indications and help to solve the puzzle that this process can be. Proper patient selection is the first step for a good surgical outcome. In this review, then, relevant considerations are discussed, involving PD genes, PD phenotypes, indications of early stages, non-motor symptoms, neuroimaging predictors, comorbidities, and age. Individualized approaches are encouraged, including clinical and radiological factors. Social support during the whole follow-up and expectations alignment are necessary through this process and are also debated.

20 June 2024 in Toxins
Verified
Journal Article
Open access
PDF file
JSJulia Carvalhinho Carlos de Souza
Julia Carvalhinho Carlos de Souza
AFAnanda Carolina Moraes Falcone
Ananda Carolina Moraes Falcone
RBRenata Montes Garcia Barbosa
Renata Montes Garcia Barbosa
MSMiriam Soares
Miriam Soares
RMRenato P. Munhoz
Renato P. Munhoz
RCRubens Gisbert Cury
Rubens Gisbert Cury
Deep Brain Stimulation (DBS) is a recognized treatment for different dystonia subtypes and has been approved by the Food and Drug Administration (FDA) since 2003. The European Federation of Neurological Societies (EFNS) and the International Parkinson and Movement Disorders Society (MDS) recommend DBS for dystonia after failure of botulinum toxin (BoNT) and other oral medications for dystonia treatment. In addition, several long-term studies have demonstrated the continuous efficacy of DBS on motor and quality of life (QoL) scores. However, there are only a few reports comparing the overall impact of surgical treatment in BoNT protocols (e.g., dosage and number of selected muscles before and after surgery). This retrospective multicenter chart-review study analyzed botulinum toxin total dosage and dosage per muscle in 23 dystonic patients before and after DBS surgery. The study’s primary outcome was to analyze whether there was a reduction in BoNT dosage after DBS surgery. The mean BoNT dosages difference between baseline and post-surgery was 293.4 units for 6 months, 292.6 units for 12 months, and 295.2 units at the last visit. The median total dose of BoNT in the preoperative period was 800 units (N = 23). At the last visit, the median was 700 units (p = 0.05). This represents a 12.5% reduction in BoNT median dosage. In conclusion, despite the limitations of this retrospective study, there was a significant reduction in BoNT doses after DBS surgery in patients with generalized dystonia.

28 July 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
CLClarice Listik
Clarice Listik
ELEduardo Listik
Eduardo Listik
FRFlávia de Paiva Santos Rolim
Flávia de Paiva Santos Rolim
MSMiriam Soares
Miriam Soares
RBRenata Montes Garcia Barbosa
Renata Montes Garcia Barbosa
RCRubens Gisbert Cury
Rubens Gisbert Cury
Deep brain stimulation (DBS) is a treatment for dystonia, with most trials conducted in developed countries. Data from developing countries like Brazil are limited. To evaluate the landscape of DBS for dystonia in Brazil, assessing motor outcomes compared with the existing literature. A retrospective multicenter cohort study was conducted via medical record review. Demographics and motor outcomes were collected and analyzed using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) from patients across four of Brazil's five macro-regions. The cohort included 60 patients (44.3% female), with DBS primarily targeting the globus pallidus internus (73.3%) or subthalamic nucleus (18.3%). The BFMDRS motor scores decreased from 63.0 ± 26.2 (n = 24) at baseline to 36.7 ± 24.6 at 1-year post-DBS (n = 22, p = 0.0018) and 43.6 ± 35.0 at the last assessment (n = 13, p = 0.0327). The use of DBS yielded significant, sustained motor improvements, consistent with developed countries, highlighting its feasibility and effectiveness in Brazil within diverse healthcare settings.

20 June 2025 in Neuromodulation: Technology at the Neural Interface
Verified
Journal Article
Closed access
RBRenata Montes Garcia Barbosa
Renata Montes Garcia Barbosa
JYJoyce Yuri Silvestre Yamamoto
Joyce Yuri Silvestre Yamamoto
MSMiriam Carvalho Soares
Miriam Carvalho Soares
IPIsabela Bruzzi Bezerra Paraguay
Isabela Bruzzi Bezerra Paraguay
SCSara Carvalho Barbosa Casagrande
Sara Carvalho Barbosa Casagrande
RCRubens Gisbert Cury
Rubens Gisbert Cury